Angela Branche, M.D.

During her years at the University of Rochester her focus in research involved the use of viral molecular and immunological diagnostic assays to explore the pathogenesis and host response to acute viral respiratory illnesses in adults. She is currently the clinical director of the NIH Center for Excellent in Influenza Research and Surveillance (CEIRS) New York Influenza Center of Excellence (NYICE) and Co-Principle Investigator for the UR Vaccine Treatment and Evaluation Unit (UR VTEU). Her current research activities explore clinical disease, pathogenesis, development of therapeutics and vaccine biology related to infection with viral and bacterial respiratory pathogens. Studies include assessment of asymptomatic carriage of Streptococcus pneumoniae and the impact of pneumococcal vaccination, surveillance of epidemic influenza infections and immunologic mechanisms of protection following natural infection versus vaccination, the development of pandemic influenza vaccines, population-based studies of RSV infection and the development of vaccine and anti-viral agents for RSV. Current efforts also include the study of the pathogenesis and immune response to pandemic SARS Coronavirus 2 infections and clinical interventional trials for the development of COVID19 therapeutic agents and vaccines. She is a member of the Infectious Disease Society of America and the NIH Human Cohorts Steering Committee and NIH IDCRC Emerging Infectious Expert Working Group. Dr. Branche has published several peer-reviewed articles, reviews and book chapters related to respiratory viral pathogens in adults.